We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

252 hedge funds and large institutions have $4.58B invested in Iovance Biotherapeutics in 2020 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 83 increasing their positions, 91 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% more call options, than puts

Call options by funds: $52.7M | Put options by funds: $26.5M

18% more capital invested

Capital invested by funds: $3.88B → $4.58B (+$704M)

0% more funds holding in top 10

Funds holding in top 10: 9 → 9 (0)

0.67% less ownership

Funds ownership: 96.25% → 95.58% (-0.67%)

9% less repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 91

10% less first-time investments, than exits

New positions opened: 46 | Existing positions closed: 51

2% less funds holding

Funds holding: 257 → 252 (-5)

Holders
252
Holders Change
-5
Holders Change %
-1.95%
% of All Funds
5.08%
Holding in Top 10
9
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.18%
New
46
Increased
83
Reduced
91
Closed
51
Calls
$52.7M
Puts
$26.5M
Net Calls
+$26.2M
Net Calls Change
-$19.2M

Top Buyers

1
AIM
ARK Investment Management
Florida
+$112M
2
Franklin Resources
Franklin Resources
California
+$41.6M
3
NAMA
Nikko Asset Management Americas
New York
+$23.5M
4
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group
Japan
+$23.3M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$13.4M

Top Sellers

1
PA
Perceptive Advisors
New York
-$52.8M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$30M
3
ACA
Avoro Capital Advisors
New York
-$25.3M
4
EAM
Eagle Asset Management
Florida
-$19.8M
5
Goldman Sachs
Goldman Sachs
New York
-$18.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
176
Two Sigma Investments
New York
$353K -$2.39M -77,873 -88%
MLICM
177
Metropolitan Life Insurance Company (MetLife)
New York
$351K -$2.36K -77 -0.7%
CF
178
CNA Financial
Illinois
$347K -$86.1K -2,810 -21%
CAG
179
Crestwood Advisors Group
Massachusetts
$346K – – –
VEA
180
Virtus ETF Advisers
New York
$344K -$43.5K -1,419 -12%
PRC
181
Pearl River Capital
Michigan
$332K -$348K -11,364 -53%
PCM
182
Prelude Capital Management
New York
$323K -$56.8K -1,852 -16%
GT
183
Glenmede Trust
Pennsylvania
$310K +$61.6K +2,008 +27%
VRS
184
Virginia Retirement Systems
Virginia
$303K -$291K -9,500 -51%
Parallax Volatility Advisers
185
Parallax Volatility Advisers
California
$301K +$280K +9,145 New
PAMU
186
Pictet Asset Management (UK)
United Kingdom
$300K +$279K +9,100 New
EAM
187
Evanson Asset Management
California
$298K – – –
TCA
188
Transcend Capital Advisors
New Jersey
$291K +$271K +8,844 New
PC
189
PA Capital
Virginia
$260K -$188K -6,133 -44%
RJFSA
190
Raymond James Financial Services Advisors
Florida
$258K -$7.48K -244 -3%
CG
191
Cutler Group
California
$257K +$239K +7,809 New
KM
192
Kalos Management
Georgia
$254K – – –
AAMU
193
Amundi Asset Management US
Massachusetts
$250K +$6.13K +200 +3%
SPC
194
Sigma Planning Corp
Michigan
$246K -$31.4K -1,023 -12%
WCM
195
Weld Capital Management
New York
$245K +$228K +7,441 New
Los Angeles Capital Management
196
Los Angeles Capital Management
California
$241K -$637K -20,766 -74%
Canada Life
197
Canada Life
Manitoba, Canada
$236K – – –
B
198
Bellecapital
Switzerland
$228K +$212K +6,928 New
LPL Financial
199
LPL Financial
California
$226K +$211K +6,869 New
VWM
200
Vigilare Wealth Management
Arizona
$223K -$64.4K -2,100 -24%
6 7
8
9 10

IOVA Hedge Fund Activity: Q3 2020 in Review

252 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q3 2020, worth a combined $4.58B — up 18% from $3.88B a quarter earlier.

Sellers outnumbered buyers: 51 funds closed out of IOVA and 46 opened new positions — a net loss of 5 holders — while 91 trimmed existing stakes and 83 added.

The largest buyer was ARK Investment Management, adding an estimated $112M. The largest seller was Perceptive Advisors, cutting an estimated $52.8M.

  • 252 institutional investors held Iovance Biotherapeutics (IOVA) as of Q3 2020, down from 257 in Q2 2020.
  • Funds reported $4.58B of Iovance Biotherapeutics stock for Q3 2020, up 18% quarter-over-quarter.
  • 46 funds opened new Iovance Biotherapeutics positions in Q3 2020 and 51 closed out, a net change of -5 holders.
  • The largest Iovance Biotherapeutics buyer in Q3 2020 was ARK Investment Management, an estimated $112M added.
  • The largest Iovance Biotherapeutics seller in Q3 2020 was Perceptive Advisors, an estimated $52.8M sold.

Based on aggregated 13F filings for Q3 2020.